AKESO News

AKESO: Notification Letter and Reply Form to Non-registered Holders - Notice of Publication of 2023 Annual Report

Apr 29 10:41 ET

AKESO: Notification Letter and Reply Form to Registered Shareholders - Notice of Publication of 2023 Annual Report

Apr 29 10:39 ET

AKESO: 2023 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

Apr 29 10:35 ET

AKESO: VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTED THE SUPPLEMENTAL NEW DRUG APPLICATION FOR CADONILIMAB (PD-1/CTLA-4) AS FIRST-LINE TREATMENT FOR CERVICAL CANCER

Apr 23 20:15 ET

AKESO: Notification Letter and Reply Form to Non-registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications

Apr 8 04:37 ET

AKESO: Notification Letter and Reply Form to Registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications

Apr 8 04:34 ET

AKESO: Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 March 2024

Apr 5 05:11 ET

AKESO: Next Day Disclosure Return

Mar 28 08:43 ET

AKESO: Monthly Return of Equity Issuer on Movements in Securities for the Month ended 29 February 2024

Mar 5 05:06 ET

AKESO: Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 January 2024

Feb 6 05:13 ET

AKESO: Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 December 2023

Jan 5 04:21 ET

AKESO: VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTED THE SUPPLEMENTAL NEW DRUG APPLICATION FOR CADONILIMAB (PD-1/CTLA-4) IN COMBINATION WITH CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR GASTRIC CANCER

Jan 4 19:22 ET

AKESO: Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 November 2023

Dec 6, 2023 04:45 ET

AKESO: VOLUNTARY ANNOUNCEMENT - AK104-303, A PHASE III TRIAL OF CADONILIMAB REACHED PROGRESSION-FREE-SURVIVAL (PFS) PRIMARY ENDPOINT AT INTERIM ANALYSIS FOR FIRST LINE TREATMENT OF CERVICAL CANCER

Nov 22, 2023 18:00 ET

AKESO: VOLUNTARY ANNOUNCEMENT - AK104-302, A PHASE III TRIAL OF CADONILIMAB IN COMBINATION WITH CHEMOTHERAPY AS FIRST LINE TREATMENT FOR GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA (GC/GEJC) REACHED PRIMARY ENDPOINT OF OVERALL SURVIVAL (OS) AT INT

Nov 6, 2023 18:00 ET

AKESO: Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 October 2023

Nov 6, 2023 04:09 ET

AKESO: Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 September 2023

Oct 6, 2023 05:00 ET

AKESO: Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 August 2023

Sep 5, 2023 05:17 ET

AKESO: VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTED THE NEW DRUG APPLICATION FOR THE EBDAROKIMAB INJECTION (IL-12/IL-23 MONOCLONAL ANTIBODY, AK101) INDEPENDENTLY-DEVELOPED BY AKESO

Aug 23, 2023 20:29 ET

AKESO: Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 July 2023

Aug 2, 2023 05:19 ET